Abstract CT195: Fast-manufactured, low IL-2-dependent FAST-TIL for the treatment of advanced melanoma in asian patients: Median 6-month follow-up data from a phase I clinical trial

Cancer Research 2026

View at publisher
Authors: Di Wu, Yuan Fang, Zhen Guo, Jie Liu, Jing Lin, Yaotiao Deng, Shijie Lan, Shuhang Wang, Ganchen Gao, Pengxiang Wang, Xinhua Zhang, Yi Zhao
+3 more Yuehua Chen, Yi Jiang, Ning Li
DOI: 10.1158/1538-7445.am2026-ct195
Cited by: 1

Abstract

Abstract Background: FAST-TIL (HS-IT101) is an innovative autologous tumor-infiltrating lymphocyte (TIL) therapy product developed using a fully enclosed, automated platform. It features minimal dependence on IL-2, requires very small amounts of starting tumor tissue (

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Immunotherapy and Immune Responses CAR-T cell therapy research

Publication details

Journal / source
Cancer Research
Publisher
American Association for Cancer Research (AACR)
Volume
86
Issue
8_Supplement
Pages
CT195–CT195
Publication date
17 April 2026
Language
EN